Folic acid, the synthetic form of vitamin B9 added to fortified foods and most supplements, requires several enzymatic steps before your body can actually use it. One of the most important enzymes in that chain is MTHFR, and common genetic variants in the gene that codes for it can slow or partially block the conversion of folic acid into its active form. The result is a mismatch: you take in folic acid, but your cells may not get enough of the finished product they need, while unconverted folic acid accumulates in your blood. How much this matters depends on which variants you carry, what else is in your diet, and what you are trying to prevent or treat.
Why Folic Acid Needs So Much Processing
Folic acid does not exist in meaningful amounts in fresh, unprocessed food. It is a fully oxidized, synthetic molecule designed for shelf stability in supplements and fortified flour. Before your cells can use it for DNA repair, neurotransmitter production, or the recycling of homocysteine, it has to be reduced and chemically rearranged through multiple steps. The first bottleneck is an enzyme called DHFR, which converts folic acid into a reduced folate form. Research on human liver tissue found that DHFR activity per gram of human liver was, on average, less than two percent of what is found in rat liver, with nearly a fivefold variation among the human samples tested.1PubMed Central. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake That means even before MTHFR enters the picture, your liver’s capacity to handle folic acid is limited and highly individual.
Once DHFR does its job, the partially processed folate still needs MTHFR to convert it into 5-methyltetrahydrofolate, commonly called 5-MTHF. This is the form that circulates in your blood, crosses into your brain, and serves as the methyl donor for converting homocysteine back into methionine. When MTHFR works normally, the system runs. When it does not, the downstream supply of 5-MTHF falls short.
What MTHFR Variants Actually Do
Two common variants in the MTHFR gene affect enzyme function. The more studied one, C677T, produces a version of the enzyme that is less heat-stable and less active. People who carry two copies of this variant (homozygotes) have roughly 60 percent of normal enzyme activity. A second variant, A1298C, has a milder effect on its own, but carrying one copy of each variant together drops activity to about 50 to 60 percent of normal, lower than carrying just one copy of C677T alone.2PubMed. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity These are not rare mutations. Roughly 10 to 15 percent of many populations are homozygous for C677T, and compound heterozygotes (one of each) make up about 15 percent of individuals.
In a cell culture study, supplementing with folic acid produced a 2.5-fold increase in intracellular 5-MTHF in cells with normal MTHFR activity, but no increase at all in cells with low MTHFR activity. When those same low-activity cells were given 5-MTHF directly instead, intracellular levels jumped tenfold.3Europe PMC. Folate Insufficiency Due to MTHFR Deficiency Is Bypassed by 5-Methyltetrahydrofolate The takeaway is stark: folic acid supplementation simply did not produce more active folate in cells that lacked adequate MTHFR function, while giving those cells the already-converted form bypassed the problem entirely.
Unmetabolized Folic Acid Builds Up
When folic acid intake exceeds what DHFR and MTHFR can process, the unconverted folic acid enters the bloodstream as what researchers call unmetabolized folic acid, or UMFA. This is not a theoretical concern limited to megadoses. Mandatory folic acid fortification of grain products, now policy in dozens of countries, reliably generates detectable UMFA in the general population because hepatic DHFR reduces folic acid only slowly.4PubMed Central. Unmetabolized Folic Acid: Biology, Epidemiology, and Clinical Consequences: A Systematic Review People who also carry MTHFR variants face a double bottleneck, since even the fraction that gets past DHFR may stall at the next step.
UMFA accumulation is tied to the saturation of DHFR, and once that enzyme is overwhelmed, unmetabolized folic acid persists in circulation even after relatively modest dietary exposure.5PubMed Central. Uncovering the Hidden Dangers and Molecular Mechanisms of Excess Folate: A Narrative Review – Section: Accumulation of Unmetabolized Folic Acid The question that has occupied researchers for the past two decades is whether this circulating UMFA is biologically inert or actively harmful.
What UMFA Appears to Do to Immune Function
One of the more consistent findings involves natural killer cells, a type of immune cell responsible for identifying and destroying virus-infected cells and early-stage tumors. In a study of postmenopausal women, those with detectable UMFA in their plasma had roughly 23 percent lower natural killer cell activity than women without detectable UMFA, and the effect grew more pronounced as UMFA concentrations increased.6PubMed. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women
An intervention study in healthy Brazilian adults made the connection more direct. After 90 days of supplementing with 5 milligrams of folic acid daily, UMFA concentrations spiked dramatically and researchers observed a significant reduction in both the number and the killing capacity of natural killer cells.7PubMed Central. A daily dose of 5 mg of folic acid for 90 days is associated with increased serum unmetabolized folic acid and reduced natural killer cell cytotoxicity in healthy Brazilian adults Five milligrams is a high supplemental dose, well above the 400 micrograms typically recommended for adults. But the direction of the finding has held across studies and is consistent with animal data showing the same pattern in aged mice.8PubMed. High folic acid intake reduces natural killer cell cytotoxicity in aged mice The immune implications remain an active area of research, and nobody is suggesting that standard fortification levels are dangerous for most people. But for individuals who metabolize folic acid poorly and accumulate more UMFA as a result, the margin between adequate intake and problematic buildup may be narrower.
Homocysteine, Heart Disease, and Neural Tube Defects
MTHFR’s main job in the body is to supply 5-MTHF, which then serves as the methyl donor that converts homocysteine back into methionine. When MTHFR is sluggish, homocysteine accumulates. Elevated homocysteine is a well-established marker associated with premature coronary artery disease.9PubMed Central. Methylenetetrahydrofolate Reductase Polymorphism and Premature Coronary Artery Disease A meta-analysis published in JAMA found that people homozygous for the C677T variant had a significantly higher risk of coronary heart disease, and that this risk was most pronounced when folate status was low.10PubMed. MTHFR 677C–>T polymorphism and risk of coronary heart disease: a meta-analysis In other words, the genetic variant alone is not destiny; it interacts with how much usable folate you have circulating.
The stakes during pregnancy are especially high. Neural tube defects, which include spina bifida and anencephaly, have long been linked to insufficient folate during early fetal development. A meta-analysis of 25 case-control studies found that mothers who were homozygous for C677T had about twice the odds of having a child with a neural tube defect compared to mothers with no copies of the variant.11PubMed Central. Association of the maternal MTHFR C677T polymorphism with susceptibility to neural tube defects in offsprings: evidence from 25 case-control studies Folic acid fortification programs have reduced neural tube defect rates globally.12PubMed Central. Folic acid food fortification-its history, effect, concerns, and future directions The irony is that women who benefit most from increased folate intake may be the same ones who process folic acid least efficiently.
Methylfolate and Folinic Acid as Alternatives
If the problem is that MTHFR variants prevent efficient conversion of folic acid into 5-MTHF, the most intuitive solution is to supplement with 5-MTHF directly. And the pharmacokinetic data supports the logic. In a head-to-head comparison, 5-MTHF raised plasma folate levels more effectively than folic acid regardless of MTHFR genotype, with a higher peak concentration and a faster time to reach that peak. Folic acid supplementation regularly produced detectable UMFA in plasma, while 5-MTHF rarely did.13REPRODUCTIVE ENDOCRINOLOGY. A study of plasma folate under the influence of [6S]-5-MTHF in women with 677C→T polymorphism of mthfr with different types of inheritance A separate pharmacokinetic study in healthy volunteers confirmed that 5-MTHF supplementation produced roughly twice the peak blood level of the active folate form compared to folic acid, while generating less than half the UMFA.14International Journal of Applied Pharmaceutics. PHARMACOKINETIC STUDY OF HY-FOLIC® AND FOLIC ACID IN HEALTHY VOLUNTEERS
Folinic acid, also known as leucovorin, represents another route around the bottleneck. Unlike folic acid, folinic acid is already in a reduced form and can enter folate metabolism without needing DHFR. It has a specific clinical role in cerebral folate deficiency, a condition in which 5-MTHF levels in the brain are abnormally low. In this context, folinic acid has been used to restore brain folate levels and has been studied as a treatment in children with autism spectrum disorders who have antibodies against the folate receptor that transports 5-MTHF into the brain.15PubMed Central. Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis
Riboflavin, the Overlooked Cofactor
MTHFR does not work alone. The enzyme requires a riboflavin-derived cofactor (FAD, made from vitamin B2) to function. When riboflavin status is poor, even people with normal MTHFR genes may have suboptimal enzyme activity. And for those carrying the C677T variant, riboflavin status can make a measurable difference. In a study examining the interaction, carriers of the 677T allele who had low-to-mid-range folate levels showed about eight percent higher homocysteine compared to people without the variant, but this effect disappeared when riboflavin status was optimal.16PubMed Central. Riboflavin status modifies the effects of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms on homocysteine Riboflavin has also drawn attention for its role in blood pressure regulation in people with the TT genotype.17PubMed. Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition
This matters practically because most conversations about MTHFR focus narrowly on folic acid versus methylfolate. If you carry a C677T variant and your riboflavin intake is also marginal, fixing the riboflavin gap alone could meaningfully improve how well your enzyme functions. Dairy, eggs, lean meats, and some fortified cereals are common dietary sources of riboflavin.
Folic Acid Can Mask Vitamin B12 Deficiency
One of the oldest and most clinically significant concerns about high folic acid intake has nothing to do with MTHFR variants, but the two problems can compound each other. Vitamin B12 deficiency classically causes a specific type of anemia with large, misshapen red blood cells. High folic acid intake can correct that anemia, making blood counts look normal and removing the most visible warning sign, while B12 deficiency continues damaging the nervous system in the background. Historical case reports documented neurological deterioration in patients with pernicious anemia who were treated with high-dose folic acid, and some clinical evidence suggests that folic acid may not merely mask the deficiency but accelerate neurological damage.18PubMed Central. Excess Folic Acid and Vitamin B12 Deficiency: Clinical Implications?
For people with MTHFR variants, this is relevant because they may be advised to take higher doses of folic acid to compensate for inefficient conversion. If a B12 deficiency is also present but unrecognized, pushing more folic acid could be counterproductive. Checking B12 status before increasing folate supplementation in any form is a prudent step.
The Folate and Cancer Paradox
Folate’s relationship with cancer is genuinely complicated and resists a simple good-or-bad framing. Low folate status has been linked to higher risks of several cancers, likely because inadequate folate leads to more DNA damage and faulty repair. That observation drove early enthusiasm for supplementation as a protective measure. But when researchers gave folic acid to patients who already had a history of colorectal polyps, the results raised alarms. Modeling studies suggest that while adequate folate helps prevent healthy cells from acquiring mutations, folic acid supplementation may help existing precancerous growths proliferate faster, since rapidly dividing cells also need folate for DNA synthesis.19PubMed Central. Does folic acid supplementation prevent or promote colorectal cancer? Results from model-based predictions The timing and context of supplementation appear to matter as much as the dose.
MTHFR and Methotrexate
Methotrexate, a drug widely used for rheumatoid arthritis and certain cancers, works by interfering with folate metabolism. People carrying MTHFR variants, who already have reduced folate processing capacity, may be more vulnerable to the drug’s side effects. A meta-analysis found that the C677T variant was associated with about a 70 percent increase in the odds of methotrexate toxicity.20PubMed Central. Meta-analysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity A study in Algerian rheumatoid arthritis patients found an even stronger association, with C677T carriers having roughly 3.6 times the odds of adverse effects from methotrexate. The same study found that the A1298C variant was instead linked to treatment response rather than toxicity, suggesting the two variants affect methotrexate therapy through different pathways.21Heliyon. Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients The overall evidence base is mixed enough that routine MTHFR genotyping before methotrexate therapy has not become standard practice, though individual clinicians sometimes order it.22PubMed. Pharmacogenetic insights into MTHFR and SLC19A1 variants in low-dose methotrexate therapy for rheumatologic diseases
The Testing Controversy
Despite widespread consumer interest in MTHFR testing, mainstream medical genetics organizations have pushed back. The American College of Medical Genetics issued a practice guideline stating that MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of a routine evaluation for blood clotting disorders.23PubMed. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing Their reasoning is that homocysteine can be measured directly and treated with B vitamins regardless of genotype, so knowing the genetic variant does not change clinical management in most situations.
This position frustrates many patients and some practitioners. The counterargument is that knowing your MTHFR status can guide the choice of folate form (methylfolate instead of folic acid) and prompt attention to cofactors like riboflavin and B12. The ACMG guideline was narrowly focused on thrombophilia workups, not on nutritional optimization, and may understate the relevance of genotype to supplement selection. Still, the guideline reflects a genuine concern that MTHFR testing results are overinterpreted, particularly in the direct-to-consumer genetics market, where a common genetic variant can be repackaged as a frightening diagnosis.
MTHFR Variants and Mental Health
A retrospective review of 186 psychiatric outpatients who were tested for MTHFR status found that those with severe MTHFR deficiency had gone through more failed medication trials than patients with normal enzyme function, and the clinic’s patient pool skewed toward moderate deficiency overall.24PubMed Central. Discovery of Methylenetetrahydrofolate Reductase (MTHFR) Deficiency in Individuals With Common Psychiatric Comorbidities: A Retrospective Case Review This fits a plausible biological story, since 5-MTHF is involved in the synthesis of serotonin, dopamine, and norepinephrine. But a retrospective chart review in a clinic that was already testing for MTHFR does not prove causation, and the study’s population was self-selected. What it does suggest is that folate metabolism deserves more attention in patients with treatment-resistant depression and anxiety, a perspective that has slowly been gaining ground but remains far from universal in psychiatry.
Why the Variant Is So Common
If reduced MTHFR function were purely harmful, natural selection would have driven the C677T variant out of the population long ago. Instead, it is present at high frequencies across many ethnic groups, which suggests it may confer some benefit under certain environmental conditions. An analysis of MTHFR variant distribution across Eurasia found that the frequency of the T allele followed a curve-shaped relationship with UV radiation levels, with intermediate UV environments having the highest frequencies.25PubMed. Is the prevalence of MTHFR C677T polymorphism associated with ultraviolet radiation in Eurasia? One hypothesis is that in regions with ample UV-driven folate destruction in the skin, a variant that shifts folate metabolism could have conferred a survival advantage under specific dietary and sunlight conditions. The evolutionary picture is incomplete, but it reinforces an important point: MTHFR variants are not defects. They are common human variation that interacts with diet, environment, and modern food processing in ways our ancestors never encountered.